<DOC>
	<DOC>NCT00357734</DOC>
	<brief_summary>The purpose of this study is to assess the long-term safety profile and the secondary objective to estimate clinical benefit of ZD1839 (gefitinib).</brief_summary>
	<brief_title>Iressa Follow-up Trial</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Provision of written informed consent to participate in the trial. Female or male aged 18 years and over. Patients with previously diagnosed cancer who have been treated with ZD1839 in a parent ZD1839 clinical trial and may benefit from continuation Known severe hypersensitivity to ZD1839 Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort. Withdrawal from a parent ZD1839 trial because of tumor progress</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>